PNC-27 is a synthetic peptide derived from the MDM-2-binding domain of the p53 tumour suppressor protein, combined with a membrane-targeting sequence. Unlike conventional cytotoxic agents, PNC-27 is proposed to exert its effects by selectively binding to HDM-2 (the human homologue of MDM-2) expressed aberrantly on the membranes of cancer cells, leading to the formation of pores and subsequent tumour cell lysis. This membrane-disrupting mechanism is of significant interest to oncology researchers, as it suggests a degree of selectivity towards malignant cells whilst leaving normal cells relatively unaffected.
PNC-27 has been investigated in preclinical research across a range of cancer cell lines, including pancreatic, breast, and leukaemia models, demonstrating cytotoxic activity in vitro. Its unique dual-domain structure — comprising a p53 transactivation domain sequence alongside a transmembrane-penetrating helix — makes it a compelling subject for studies into peptide-based cancer therapeutics and membrane-active compounds.
Store at -20°C, protected from light and moisture. Reconstitute in sterile water or bacteriostatic water prior to use.
Molecular Formula
C₁₅₀H₂₅₀N₄₄O₄₃S₁
Molecular Weight
3377 g/mol
Purity
>98%
CAS Number
1159417-94-3
Form
Lyophilised Powder
Research Applications
Oncology research, Cancer cell biology, Apoptosis and cell death studies, Membrane-active peptide research, p53 pathway investigation, Tumour suppressor protein studies
For research purposes only. Not for human use.
Reviews
There are no reviews yet.